![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intellia Therapeutics Inc | NASDAQ:NTLA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.51 | 1.96% | 26.52 | 26.47 | 26.54 | 26.90 | 25.92 | 26.36 | 339,642 | 15:31:36 |
By Kimberly Chin
Intellia Therapeutics Inc. said the U.S. Food and Drug Administration has granted its acute myeloid leukemia treatment an orphan drug designation.
NTLA-5001 is an autologous T-cell receptor therapy that targets the Wilms' Tumor antigen, which is a common expression in acute myeloid leukemia and other hematologic and solid tumors.
The treatment is currently being reviewed in a Phase 1/2a study in adults who have a detectable sign of the disease and have received standard first-line treatment, the clinical-stage genome editing company said.
The FDA's designation is granted to drugs that are intended for the treatment, diagnosis or prevention of rare diseases that can affect fewer than 200,000 people in the U.S. Drugs that receive the designation can qualify companies for certain tax credits, prescription drug user-fee exemptions and a seven-year marketing exclusivity once the drug is approved by the FDA.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
March 09, 2022 16:38 ET (21:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Intellia Therapeutics Chart |
1 Month Intellia Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions